I guess 2011 is then the earliest that product like this may be on market. One thing that strikes me is that IDIXs stated goal is once-a-day therapy in HIV, whereas the current testing is qd. Do you think another 1-2 yrs is necessary for a different formulation?
It also seems strange that no new NNRTI has been approved since 1998. Is it right to assume this is because the current ones work well enough and the only improvements are in dosing and in resistant strains?
Market Data 
Markets 
AI
